Effect of Dehydroepiandrosterone Administration in Patients With Poor Ovarian Response According to the Bologna Criteria

Chinese Medical Association

Status: Completed

Conditions: Infertility

Treatments: Drug: DHEA

Study type: Observational

Funder types: NETWORK

Identifiers

NCT02132559

NSFC30901601

Details and patient eligibility

About

Women with low ovarian reserve typically respond less well to the drugs used to stimulate the ovary during IVF treatment and produce fewer eggs and, as a result, are less likely to fall pregnant either naturally or after fertility treatment. The ideal stimulation regimen for poor responders is currently unknown.

Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy chances for poor responders, and is now utilized by approximately one third of all IVF centers world-wide. However, the current clinical evidence for DHEA on improvement of ovarian response and IVF outcome is insufficient. The validity of the results of the former studies, especially the varied inclusion criteria used to specify poor responders, is a subject of debate. Recently a uniform definition on poor ovarian response, the Bologna criteria, has been proposed by the European Society for Human Reproduction and Embryology(ESHRE). However, no studies have been performed study to evaluate the potential effects of DHEA supplementation according to these standards.

The purpose of this study is to assess the impact of DHEA supplementation on IVF outcome of poor ovarian responders that fulfill the Bologna criteria.

Enrollment: 386 patients

Sex: Female

Ages: 23 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Patients with poor ovarian response according to the Bologna criteria

Exclusion criteria

women aged > 45 years or baseline follicle stimulating hormone(FSH)levels >40 IU/l.

Trial design

386 participants in 1 patient group

DHEA administration,no treatment

Description:

The patients of study group received DHEA 25 mg orally,three times a day before the IVF cycle. Except for IVF, the control group of patients did not receive any pre-treatment.

Treatment:

Drug: DHEA